300630，重大财务造假！启动终止上市程序！

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed strict administrative penalties on Hainan Puli Pharmaceutical Co., Ltd. (referred to as *ST Puli) for significant financial fraud, leading to the initiation of delisting procedures by the Shenzhen Stock Exchange [2][4]. Summary by Sections Financial Fraud Details - *ST Puli's annual reports for 2021 and 2022 contained major false records, with a total profit inflation exceeding 500 million yuan, accounting for over 50% of the reported profits [2][4]. - The company falsely reported a total revenue of 1.03 billion yuan and a profit total of 695 million yuan over the two years, representing 31.08% and 76.72% of the disclosed annual figures, respectively [4]. Regulatory Actions - The CSRC has stated that administrative penalties and forced delisting are not the end of the process, as they will pursue comprehensive accountability for the involved parties [6][7]. - The CSRC will collaborate with relevant departments to implement a multi-faceted accountability system, including criminal referrals for any potential criminal evidence [7]. Investor Protection Measures - The China Securities Investor Services Center will actively assist eligible investors who suffered losses due to the financial fraud, utilizing various legal methods to protect their rights [7]. - The CSRC is enhancing its comprehensive prevention and punishment mechanisms against financial fraud, emphasizing the importance of a three-pronged accountability system involving administrative, civil, and criminal measures [8]. Market Impact - The CSRC has significantly increased its enforcement actions, with 739 cases handled in 2024, resulting in 592 administrative penalties and a total fine amounting to 15.342 billion yuan, which is 2.4 times that of 2023 [8]. - The regulatory body aims to intensify the crackdown on financial fraud in the capital market, ensuring that the costs of violations are raised and that accountability is firmly established [8].